KPTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KPTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Karyopharm Therapeutics's accounts receivables for the quarter that ended in Sep. 2024 was $31.8 Mil.
Accounts receivable can be measured by Days Sales Outstanding. Karyopharm Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 was 74.77.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Karyopharm Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-1.51.
The historical data trend for Karyopharm Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Accounts Receivable | Get a 7-Day Free Trial | 7.86 | 12.88 | 22.50 | 47.09 | 26.96 |
Karyopharm Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Accounts Receivable | Get a 7-Day Free Trial | 37.92 | 26.96 | 31.08 | 38.00 | 31.78 |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Karyopharm Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 31.778 | / | 38.783 | * | 91 |
= | 74.77 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Karyopharm Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Karyopharm Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (133.526 | + | 0.75 * 31.778 | + | 0.5 * 4.672 | - | 349.123 |
- | 0 | - | 0) | / | 125.303 | ||
= | -1.51 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of Karyopharm Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard A. Paulson | director, officer: President and CEO | 85 WELLS AVENUE, NEWTON MA 02459 |
Michael Mason | officer: EVP, CFO, Treasurer | 300 3RD STREET, CAMBRIDGE MA 02142 |
Michael Mano | officer: SVP, General Counsel&Secretary | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Sohanya Roshan Cheng | officer: SVP Sales & Commercial Ops | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Stuart Poulton | officer: EVP, Chief Development Officer | 85 WELLS AVENUE, NEWTON MA 02459 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Reshma Rangwala | officer: EVP & Chief Medical Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Garen G Bohlin | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451 |
Zhen Su | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Stephen Mitchener | officer: SVP, Chief Business Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Ran Frenkel | officer: EVP, WW Development Operations | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459 |
Jatin Shah | officer: EVP, Chief Medical Officer | C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Sharon Shacham | officer: C.S.O & Pres. of Res & Develop | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Michael Kauffman | director, officer: President, C.E.O., C.M.O. | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
From GuruFocus
By PRNewswire • 12-03-2024
By PRNewswire • 10-31-2024
By PRNewswire • 07-01-2024
By PRNewswire • 07-31-2024
By GuruFocus News • 11-05-2024
By PRNewswire • 08-01-2024
By PRNewswire • 11-01-2024
By GuruFocus News • 11-15-2024
By PRNewswire • 08-06-2024
By GuruFocus Research • 08-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.